Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma has a planned Rule 144 sale of 495860 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of 20523645.4 and 427247489 shares outstanding. The shares are expected to be sold on or about 01/07/2026 on NASD. They were originally acquired from the issuer in a private transaction on 06/16/2020, with 495860 shares received on that date.
Over the past 3 months, the person for whose account the securities are to be sold and related entities have already sold multiple blocks of common stock, including 3000 shares on 11/19/2025 for gross proceeds of 113364 and 110000 shares on 12/03/2025 for 4375008. Additional sales by entities such as GWL 2014 G LLC, GWL 2020 G LLC, GWL 2023 G HoldCo LLC, and GWL 2021 G LLC are also listed, reflecting an ongoing disposition program.
Royalty Pharma plc’s EVP & CFO Terrance P. Coyne reported indirect sales of Class A Ordinary Shares through entities associated with him. On January 2, 2026, TPC RP 2021, LLC sold 65,832 Class A shares and TPC RP EPA1 LLC sold 3,750 Class A shares, both at a weighted average price of $38.4157 per share, under a Rule 10b5-1 trading plan adopted on August 8, 2025.
After these trades, TPC RP 2021, LLC held 460,828 Class A shares and TPC RP EPA1 LLC held 39,760 Class A shares, reported as indirect holdings for Coyne. Additional indirect holdings include shares held through the reporting person’s and spouse’s IRAs and by the spouse, as well as partnership and Royalty Pharma Holdings Ltd interests exchangeable into 6,448,180 and 1,807,277 Class A shares, respectively, with the latter subject to vesting conditions.
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported selling 20,000 Class A Ordinary Shares on December 16, 2025. The sale, coded as "S," was executed at a weighted average price of $38.321 per share, with individual trades ranging from $38.24 to $38.40. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.
Following this activity, Urist reports beneficial ownership of 140,000 Class A shares indirectly through Sandy Lamm LLC, 19,020 shares indirectly through an IRA, and 7,398 shares held directly. In addition, Urist and related family vehicles hold limited partnership interests exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into a further 1,356,528 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc executive vice president and chief financial officer Terrance P. Coyne reported selling Class A ordinary shares of Royalty Pharma plc on 12/15/2025 under a pre-arranged Rule 10b5-1 trading plan. The filing shows a sale of 65,832 Class A shares at a weighted average price of $38.3601 per share, with individual trades occurring between $38.10 and $38.48 per share.
After these transactions, Coyne continues to report indirect beneficial ownership of 526,660 Class A shares through TPC RP 2021, LLC and 43,510 Class A shares through TPC RP EPA1 LLC, along with additional holdings in IRA and spouse accounts. The remarks also state that entities controlled by him hold interests exchangeable into 6,448,180 Class A shares and Class E shares exchangeable into 1,807,277 Class A shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc (RPRX) EVP & CFO Terrance P. Coyne reported insider stock sales in a Form 4 filing. On 11/24/2025, multiple sales of Class A ordinary shares were executed, including 55,146 shares held indirectly through TPC RP 2021, LLC at a weighted average price of $38.6663 per share and 10,686 shares at a weighted average price of $37.9604 per share. Additional smaller sales were reported through TPC RP EPA1 LLC.
After these transactions, Coyne continues to hold significant indirect stakes, including 669,010 Class A ordinary shares via TPC RP 2021, LLC and 51,634 Class A ordinary shares via TPC RP EPA1 LLC, plus various IRA and spousal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A ordinary shares and 1,807,277 Class E ordinary shares of Royalty Pharma Holdings Ltd, some of which are subject to vesting conditions. All reported sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025.
Royalty Pharma plc executive George W. Lloyd, EVP, Investments & CLO, reported multiple sales of Class A Ordinary Shares of RPRX on 11/19/2025. The transactions, coded as open-market sales, were executed under a Rule 10b5-1 trading plan adopted on August 20, 2025, meaning they followed a pre-set schedule. Shares were sold indirectly through several family-related entities, with weighted average prices generally between about $37.77 and $39.34 per share, and smaller sales from directly held shares.
After the reported sales, Lloyd continues to hold Class A Ordinary Shares through multiple vehicles, as well as limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 7,527,320 Class A Ordinary Shares. He also holds 1,944,471 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, some of which may convert into an equivalent number of Class A Ordinary Shares upon vesting.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported open-market sales of Class A Ordinary Shares of Royalty Pharma plc (RPRX) on 11/17/2025. The transactions, made under a Rule 10b5-1 trading plan adopted on August 8, 2025, included the sale of 65,844 Class A Ordinary Shares by TPC RP 2021, LLC at a weighted average price of $39.3041 per share and 3,750 Class A Ordinary Shares by TPC RP EPA1 LLC at a weighted average price of $39.304 per share.
Following these trades, the filing reports 724,156 Class A Ordinary Shares held indirectly through TPC RP 2021, LLC and 54,760 Class A Ordinary Shares held indirectly through TPC RP EPA1 LLC, along with additional indirect and direct holdings through IRAs, a spouse’s IRA, and personal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and ownership of 1,807,277 Class E Ordinary Shares of Royalty Pharma Holdings Ltd that may convert into an equivalent number of Class A Ordinary Shares upon vesting.
Royalty Pharma (RPRX) CEO and Chairman Pablo G. Legorreta reported an exempt acquisition of Class A Ordinary Shares. On 11/05/2025, he acquired 36,559 shares at $0 (code A) pursuant to Rule 16b-3 in connection with the settlement of Equity Performance Awards.
Following the transaction, his direct beneficial ownership stands at 940,955 shares. He also reports indirect holdings through various entities, including 1,040,410 shares by the Legorreta Children 2002 Trust and 901,590 shares by the GST-Exempt Legorreta 2012 Family Trust.
Royalty Pharma (RPRX) EVP & CFO reported an exempt acquisition of 6,168 Class A Ordinary Shares on 11/05/2025 at $0 per share under Rule 16b-3, tied to the settlement of Equity Performance Awards.
Following this transaction, 58,510 shares were beneficially owned through TPC RP EPA1 LLC. The filing also lists additional holdings in various accounts, including 1,500 shares held directly and 790,000 shares held indirectly by TPC RP 2021, LLC.
Royalty Pharma plc (RPRX) reported an insider transaction on a Form 4. The EVP, Investments & CLO acquired 6,168 Class A Ordinary Shares on 11/05/2025 at $0, an exempt acquisition under Rule 16b-3 tied to the settlement of Equity Performance Awards.
Following the transaction, the reporting person lists beneficial ownership across multiple indirect entities, including GWL 2023 G HoldCo LLC, GWL 2013 NG, LLC, an IRA, GWL 2014 G, LLC, GWL 2020 G, LLC, GWL 2021 G, LLC, and by spouse, as well as 3,000 shares held directly.